Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus roll-over study for patients benefiting after prior Novartis everolimus trials
NL-OMON38738Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of everolimus in Carcinoid Tumor (CT) (2 arms), sponsored by Novartis. Primary endpoint: Number of patients receiving everolimus. Started May 2013; status: active, not recruiting.
02
Drugs
everolimus
03
Conditions
Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NL-OMON38738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38738.